Press Release
Recipient of the PETRONAS National Inventor Award Joins DNA Phenomics' Management Team
Mathavan A. Chandran to Direct Product and Service Development of Life Science Research Company
KUALA LUMPUR, Malaysia – August 8, 2003 - DNA Phenomics Sdn Bhd, a development-stage company focused on the emerging field of phenomics and the discovery of genomic-based diagnostic tests, announces that Mr. Mathavan A. Chandran has agreed to join its management team as Vice President of Business Development.
"I am thrilled Matt will be joining our management team to help implement our very ambitious plans for growth," said Mr. Ezehan Kamaluddin, DNA Phenomics' Chief Operating Officer. "Matt brings broad experience and strong networking ties in a number key areas, with the pharmaceutical market being one of the most important areas given our strategic plans. As the 1995 recipient of the country’s highest honor in science and industry (the PETRONAS and Ministry of Science, Technology and Environment's Inventor of the Year Award), Matt is well known and greatly admired across the region. His success in business and accomplishments in science speak for themselves. We are very fortunate to have Matt on our team."
"As most of us already know, recent developments in the life sciences industry has created a lot of excitement and hopes within the scientific community, among the public, and especially among investors," said Mathavan Chandran. "What impressed me most about DNA Phenomics is their strategic direction and the core competencies of the team members they have assembled. These assets clearly add value and will be recognized as particularly relevant in the commercial world. This opportunity is definitely not to be missed."
Mathavan A. Chandran began his career in 1992 as a research and development chemist at METACORP BHD, the largest inorganic chemical producer in Malaysia. In 1995, Matt became the Regional Business Development Manager (chemical sector) for Peregrine International, a Hong Kong based direct investment company. He was jointly responsible for conceptualizing, evaluating, implementing, and advising start up operations, while monitoring Peregrine’s business plans across the Asia-Pacific region. Subsequently, he worked for the Belgian petrochemical-pharmaceutical multinational, UCB Pharma, as the Regional Sales and Marketing Manager for the Specialty Chemicals Business Unit in Asia-Pacific. More recently, Matt has served as principal consultant for a number of large multinationals covering ICT, financial institutions, automotive, and telecommunication. In the last two years, Matt has fostered several early stage biotechnology and bioinformatics initiatives.
About DNA Phenomics
DNA Phenomics is a development stage company focused on the emerging field of phenomics and engaged in the discovery of genomic-based diagnostic tests for personalized medicine. The company's phenomics discovery platform offers university labs as well as pharmaceutical and life science companies a powerful research tool for uncovering patterns in the genome associated with health factors and drug responses. The company’s goal is to become a leader in the discovery, development, and sale of genomic-based diagnostic healthcare products and biotech research services throughout Asia and the Pacific. Founded in 2003, DNA Phenomics is headquartered in Kuala Lumpur, Malaysia. DNA Phenomics is a privately-held company. Additional information about DNA Phenomics and its genomic-based solutions can be found at www.DNAphenomics.com.
AI
